• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Elucidation of the mechanism of polymyxin B column therapy for rapidly progressive interstitial lung disease

Research Project

Project/Area Number 17K09605
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Research Field Respiratory organ internal medicine
Research InstitutionNiigata University

Principal Investigator

Ohashi Kazumasa  新潟大学, 医歯学総合病院, 特任助教 (50463998)

Co-Investigator(Kenkyū-buntansha) 坂上 拓郎  熊本大学, 大学院生命科学研究部(医), 教授 (00444159)
高田 俊範  新潟大学, 医歯学総合病院, 特任教授 (40361919)
林 正周  新潟大学, 医歯学総合病院, 助教 (40463997)
朝川 勝明  新潟大学, 医歯学総合病院, その他 (60599158)
Project Period (FY) 2017-04-01 – 2020-03-31
Project Status Completed (Fiscal Year 2019)
Budget Amount *help
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2019: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
KeywordsPMX / ILD / PMX-DHP / 間質性肺炎 / サイトカイン
Outline of Final Research Achievements

Some patients with rapid progressive interstitial lung disease (ILD) are resistant and fatal to steroids as well as immunosuppressants. We found that rapid progressive ILD treated with polymyxin B column therapy (PMX-DHP) on the first day of steroid pulse therapy had a significantly better prognosis than the other patients. The purpose of this study was to clarify the exacerbating factors of rapidly progressive ILD by comprehensively measuring the serum concentrations of 38 cytokines before PMX-DHP, after PMX-DHP, and after steroid pulse therapy. 14 patients treated with PMX-DHP and steroid pulse therapy for rapidly progressive ILD at our hospital were enrolled. Five cytokines were significantly decreased after PMX-DHP, and more decreased after steroid pulse therapy. However, only eotaxin was decreased after PMX-DHP (p<0.05), but increased after steroid pulse therapy (p<0.05).

Academic Significance and Societal Importance of the Research Achievements

急速進行性間質性肺疾患(ILD)は難治性で致死的となる症例が多いが、PMX-DHP療法を併用することにより急速進行性ILDの予後が改善する報告があった。そこでPMX-DHP療法とステロイド治療を施行した14例を対象にPMX前後、ステロイドパルス療法後の3時点で、38種類の血清サイトカイン濃度を測定し急速進行性ILDの増悪因子を明らかにすることが目的とした。その中で血清Eotaxin濃度はPMX療法後に有意に低下したがステロイドパルス療法後は再び増加していたことが判明した。上記よりEotaxinがPMX-DHP治療によっても増悪する急速進行性ILDの病態に関与している可能性が示唆された。

Report

(4 results)
  • 2019 Annual Research Report   Final Research Report ( PDF )
  • 2018 Research-status Report
  • 2017 Research-status Report
  • Research Products

    (4 results)

All 2019 2017

All Presentation (4 results) (of which Int'l Joint Research: 1 results)

  • [Presentation] 急性呼吸不全に対するエンドトキシン吸着(PMX-DHP)療法に伴う血清サイトカイン濃度の変化2019

    • Author(s)
      大橋和政
    • Organizer
      第59回日本呼吸器学会学術講演会
    • Related Report
      2019 Annual Research Report
  • [Presentation] Analysis of Serum Cytokine Changes Caused by PMX-DHP Therapy for Acute Respiratory Failure2019

    • Author(s)
      K.Ohashi
    • Organizer
      American Thoracic Society International Conference 2019
    • Related Report
      2019 Annual Research Report
    • Int'l Joint Research
  • [Presentation] 急性呼吸不全に対するエンドトキシン吸着(PMX-DHP)療法に伴う血清サイトカイン濃度の変化2019

    • Author(s)
      大橋和政
    • Organizer
      第59回日本呼吸器学会学術講演会
    • Related Report
      2018 Research-status Report
  • [Presentation] 急性呼吸不全に対するエンドトキシン吸着(PMX-DHP)療法に伴う血清サイトカイン濃度の変化2017

    • Author(s)
      大橋和政
    • Organizer
      第57回日本呼吸器学会学術講演会
    • Related Report
      2017 Research-status Report

URL: 

Published: 2017-04-28   Modified: 2021-02-19  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi